Table 1 Characteristics of our prospective cohort study ^a

Gender (male)

23 (50%)

Age (years), mean (±SD)

56 ± 17

H1N1 status

26 (57%)

Death in ICU

15 (33%)

TISS-28, median (IQR)^b

21 (19 to 25)

SAPS II, median (IQR)^b

51 (41 to 60)

APACHE II, median (IQR)^b

22 (17 to 26)

SOFA, median (IQR)^b

9 (7 to 11)

Asthma

2 (4.3%)

COPD

11 (24%)

Smokers

9 (20%)

Alcoholic disease

5 (11%)

Diabetes mellitus

12 (26%)

Immune-compromising disorder

16 (35%)

Hospital-acquired pneumonia

31 (67%)

Bacterial pathogen

28 (61%)

Pneumococcus

6

Chlamydia/Mycoplasma

3

Legionella

2

Gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella, Morganella morganii)

9

Staphylococcus aureus

4

Other gram-positive cocci (Enterococci, coagulase-negative Staphylococci)

4

Antibiotics given during ICU

31 (67%)

Antibiotics given before ICU

15 (33%)

Mechanical ventilation

34 (74%)

Length of ventilation (days), median (IQR)

7 (1 to 11)

ECMO

5 (11%)

Renal replacement therapy

9 (19.6%)

Vasopressor therapy

30 (65%)

Length of stay (days), median (IQR)

9 (5 to 16)

Procalcitonin (μg/L) at admission (n = 36)

0.85 (0.3 to 4.1)

Procalcitonin (μg/L) within day 1 (n = 30)

0.9 (0.2 to 6)

C-reactive protein (mg/L) at admission (n = 40)

159 (61 to 253)

C-reactive protein (mg/L) within day 1 (n = 30)

101 (62 to 208)